RAB4A

Across TCGA pan-cancer cohorts, RAB4A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RAB4A data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RAB4A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB4A expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, LSCC, and PDAC are the cancer types where RAB4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.843	0.623	.002	13	view →
LSCC	DFS	Median	II,III,IV	0.671	0.882	.009	10	view →
PDAC	OS	Quartile	III,IV	0.915	0.241	.004	10	view →
CCRCC	OS	Median	II,III,IV	0.849	0.630	.020	5	view →
HNSC	DFS	Median	III,IV	0.903	1.000	.004	4	view →
UCEC	OS	Median	All	0.969	0.846	.020	4	view →
LUAD	DFS	Median	II,III,IV	0.359	0.623	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RAB4A–GBM (DFS)

Open the GBM breakdown →